A Randomized , Double-Blinded , Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor ( rhuLIF , Emfilermin , AM 424 ) to Prevent Chemotherapy-Induced Peripheral Neuropathy